ChromaDex
CompanyUnited States
ChromaDex develops one asset, in phase 1 (Niagen in fatigue). Mostly supplement acting on Mitochondrial biogenesis (PGC-1α), sirtuin signalling and NAD+ metabolism; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 1
- 1
- Trial
- 13
- Signals
Pipeline
1Nicotinamide riboside acts as an NAD+ precursor to increase NAD+ levels.
Phase 1, Supplement, Mitochondrial biogenesis (PGC-1α), Sirtuin signalling, fatigue, pharmacokinetic
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms4
- Trials7
- Signals20
- Similar companies6